[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522606":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":20,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"CellSight Technologies, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Advanced non small cell lung cancer (NSCLC) patients","EXPERIMENTAL","Patients will undergo two \\[18F\\]F AraG PET\u002FCT scans within 7 days of each other prior to receiving treatment",[13],"Drug: [18F]F-ARAG PET",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","[18F]F-ARAG PET","Two imaging sessions",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Muhammad Furqan, M.D.","Holden Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Amy Mundisev","CONTACT","319-356-1445","amy-mundisev@uiowa.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University of Iowa Hospitals and Clinics","RECRUITING","Iowa City","Iowa","52246","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-91.53017,41.66113,{"lat":45,"lon":44},[48],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[52],{"name":53,"class":54},"University of Iowa","OTHER","100522606","phase-2-test-retest-evaluation-of-18ff-arag-pet-100522606",false,"NCT06084806","Test-retest Evaluation of [18F]F-AraG PET","Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients","Inclusion Criteria:\n\n1. Patients (\\>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced\u002Fmetastatic disease.\n2. Measurable disease.\n3. ECOG performance status of 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Serious comorbidities that in the opinion of the investigator\u002Fsponsor could compromise protocol objectives.\n2. Pregnant women or nursing mothers.\n3. Patients with severe claustrophobia.","ALL","18 Years",{"count":65,"type":66},10,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This pilot study aims to evaluate the test-retest variability of \\[18F\\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \\[18F\\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \\[18F\\]F-AraG PET\u002FCT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.",[72],"Non-small Cell Lung Cancer","2024-10-22",{"date":75,"type":76},"2024-10-24","ACTUAL",{"date":78,"type":76},"2023-10-31",{"date":80,"type":66},"2025-10-31",{"name":5,"class":6},1]